The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT03879863 PHASE3 COMPLETED Results posted

The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

Details

Lead sponsor	Aldeyra Therapeutics, Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	422
Start date	Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Dry Eye

Interventions

• Reproxalap Ophthalmic Solution (0.25%) QID
• Vehicle Ophthalmic Solution QID
• Reproxalap Ophthalmic Solution (0.25%) QID to BID
• Vehicle Ophthalmic Solution QID to BID

Countries

United States